# Exceptional Responders With Solid Tumor Cancer to Chemotherapy

> **NCT02555735** · — · ENROLLING_BY_INVITATION · sponsor: **Adera Labs, LLC** · enrollment: 250 (estimated)

## Conditions studied

- Solid Tumor Neoplasms

## Interventions

- **DRUG:** Standard of Care Chemotherapy

## Key facts

- **NCT ID:** NCT02555735
- **Lead sponsor:** Adera Labs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2015-10
- **Primary completion:** 2026-12
- **Final completion:** 2027-08
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555735, "Exceptional Responders With Solid Tumor Cancer to Chemotherapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02555735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*